会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明公开
    • ONCOLYTIC ADENOVIRUS FOR TARGET THERAPY OF HUMAN TUMOR AND USE THEREOF
    • 对人类肿瘤溶瘤腺病毒治疗的目的及其用途
    • EP2682459A4
    • 2014-12-10
    • EP12752828
    • 2012-02-29
    • BEIJING BIO TARGETING THERAPEUTICS TECHNOLOGY INC
    • WANG YAOHEJIANG GUOZHONGWANG PENGJUGAO DONGLINGLEMOINE NICK
    • C12N7/01A61K31/711A61K35/76A61K38/00A61K48/00C07K14/54C12N15/24C12N15/86C12N15/861
    • A61K31/711A61K35/761A61K38/00C07K14/5434C12N15/86C12N2710/10332C12N2710/10343
    • Provided is an oncolytic adenovirus Ad-TD-hIL12 for target therapy of human tumor, which is deposited in China Center for Type Culture Collection with an accession number CCTCC NO: V201031. The viral vector is C-subclass type 5 adenovirus Ads, which has three genes E1A-CR2, E1B19K and E3gp-19K deleted, and expresses p35 and p40 subgroup gene sequences of human IL12 under the control of the E3gp-19K promoter. Oncolytic cells are replicated in tumor cells by infecting the tumor cells with the viruses, and at the same time, hIL2 having a variety of anti-tumor effects is produced in the tumor tissue at a high level. hIL12 has the effect of anti-tumor angiogenesis, can regulate the body's immunity to make the body produce specific anti-tumor immunity, kill distant metastatic tumor cells, and prevent tumor recurrence. The viral vector of the present invention can be used as a targeting genetic engineering drug for treating various solid tumors, not only can be used for intratumoral injection, can also be used for intraperitoneal and intrathoracic injection, without causing significant side effects, thus having better efficacy and safety.
    • 本发明提供一种溶瘤腺病毒,其在中国的中心沉积的典型培养物保藏CCTCC NO的登录号的Ad-TD-hIL12为人类肿瘤的靶向治疗,所有:V201031。 所述病毒载体是C-子类5型腺病毒广告,其中有三个基因E1A-CR2,E1B19K和E3gp-19K删除,和人IL-12的E3gp-19K启动子的控制下,快车的p35和p40亚组的基因序列。 溶瘤细胞在肿瘤细胞中通过与病毒感染肿瘤细胞复制,并且在在Sametime,被在肿瘤组织中以高水平产生具有各种抗肿瘤作用HIL2。 hIL12具有抗肿瘤血管生成的作用,可以调节人体的免疫力,使身体产生特异性的抗肿瘤免疫,杀远处转移肿瘤细胞,和防止肿瘤复发。 本发明的病毒载体可以用作靶向基因工程药物用于治疗各种实体瘤,不仅可用于瘤内注射,因此可以用于腹膜内和胸腔内注射,而不引起显著的副作用,因此具有更好的 疗效和安全性。